Researchers unexpectedly find new vaccine which is effective to hepatitis B

A new anti-grass pollen allergy vaccine (BM32) also can be effective against hepatitis B virus infection. The study used a lot of recombinant proteins such as recombinant horse proteins and was conducted by the Institute of Physiology, Medical University of Vienna pathology experts, published in the journals EBioMedicine.

BM32 vaccine is developed based on innovative recombinant peptide - carrier technology. Compared with other immunotherapies, the technology shows fewer side effects on allergy sufferers. The technology was conducted under the dominant of Rudolf Valenta from Medical University of Vienna.

In a IIb Phase trial led by the research institution, Carolin Cornelius found that BM32 can also resist hepatitis B virus infection when it prevent grass pollen allergy at the same time. Cornelius said, "We can prove that for those people who weren’t vaccinated with hepatitis B vaccine previously, the effective resistance rate against hepatitis B virus would reach 80% after taking BM32 vaccine." Related researchers said that the concept of peptide - carrier fusion proteins perhaps would provide new ideas for the development of immunotherapy which can improve hepatitis B infection in the future.

Cornelius continued, "We are currently researching on whether the vaccine is able to specifically resist hepatitis B virus. Hepatitis B virus infection is very common nowadays. About 350 million people worldwide carry the hepatitis B virus in the blood. For people who have taken hepatitis B vaccine, there is also 5-10% of them may respond to the virus." Flarebio provides you with good-quality recombinant proteins like recombinant ITGB2.